Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.bioMerieux, a provider of in vitro diagnostics, has concluded an agreement to acquire Sweden-based AB Biodisk. This is bioMerieux's fourth acquisition in two years.
Subscribe to our email newsletter
The AB Biodisk product portfolio is said to be very complementary to bioMerieux’s culture media and automated Vitek range for antibiotic susceptibility testing. The addition of the Etest will bring patients and customers a high medical-value test result for critical infections and critical patient treatment, where a precise minimum inhibitory concentration valuation is needed.
The AB Biodisk product range will also be an asset for use in pharmaceutical companies’s new drug development, boosting bioMerieux’s theranostics business.
bioMerieux will commercialize the AB Biodisk’s products under the bioMerieux brand through its global network in 150 countries, expanding its international footprint.
Stephane Bancel, CEO of bioMerieux, said: “For the past 18 months, bioMerieux has been following an ambitious strategy in microbiology, building on our leadership position with an enhanced portfolio of innovative solutions to better serve our customers.”